News from amsterdam molecular therapeutics (amt) b.v A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

16 Nov, 2012, 06:00 GMT Listing Amsterdam Molecular Therapeutics Terminates and Company and its Shares Cease to Exist

Amsterdam Molecular Therapeutics (AMT) Holding NV in liquidation (in liquidatie) (Euronext: AMT) announces that during the action period...


06 Nov, 2012, 13:28 GMT Amsterdam Molecular Therapeutics (in Liquidation) Announces Delisting and Expected Finalisation of Liquidation Process

Amsterdam Molecular Therapeutics (AMT) Holding NV in liquidation (in liquidatie) (Euronext: AMT) announces that NYSE Euronext has determined and...


12 Sep, 2012, 12:18 BST Amsterdam Molecular Therapeutics (in Liquidation) Announces Publication Account and Justification

Amsterdam Molecular Therapeutics (AMT) Holding NV in liquidation (in liquidatie) (Euronext: AMT) has been dissolved on April 5 2012. The account and...


13 Jul, 2012, 18:11 BST Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting

Amsterdam Molecular Therapeutics (AMT) Holding NV (in liquidation) (Euronext: AMT) published its Annual Report and Accounts for the year ended...


26 Apr, 2012, 19:43 BST Amsterdam Molecular Therapeutics Reports Full Year Results 2011

Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) (Euronext: AMT), today reported its results for the year to December 31, 2011....


26 Apr, 2012, 19:00 BST Amsterdam Molecular Therapeutics Completes Advance Distribution of uniQure Depositary Receipts to AMT Shareholders

Amsterdam Molecular Therapeutics (AMT) Holding N.V. in liquidation (in liquidatie) (Euronext: AMT), today announces that the advance distribution of...


23 Apr, 2012, 10:29 BST Amsterdam Molecular Therapeutics Receives Further Opinion on Glybera® Marketing Authorisation Application

Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidatie) (Euronext: AMT), a leader in the field of human gene therapy, has received notice ...


17 Apr, 2012, 19:44 BST Amsterdam Molecular Therapeutics Reconfirms Timetable of Principle Events of its Liquidation Process

Amsterdam Molecular Therapeutics (AMT) Holding N.V. in liquidation (in liquidatie) (Euronext: AMT), today reconfirms the earlier announced timetable...


05 Apr, 2012, 20:25 BST Amsterdam Molecular Therapeutics Announces Completion of Disposal of its Operations to uniQure B.V. and its Dissolution Becoming Effective

Amsterdam Molecular Therapeutics (AMT) Holding N.V. in liquidation (in liquidatie) (Euronext: AMT), announces that following the approval of the...


30 Mar, 2012, 19:19 BST Amsterdam Molecular Therapeutics Announces Results of Extraordinary General Meeting

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced that the Extraordinary General Meeting (EGM) ...


28 Mar, 2012, 08:31 BST Amsterdam Molecular Therapeutics Publishes Positive Data from Glybera® 14 Week Study

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today data demonstrating that one-time...


21 Feb, 2012, 06:00 GMT Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera®

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has received a request to...


17 Feb, 2012, 06:00 GMT Amsterdam Molecular Therapeutics Business to be Acquired by uniQure BV

Not for release, publication or distribution in whole or in part, directly or indirectly, in or into the United States or to US persons. This...


30 Jan, 2012, 06:00 GMT Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation And Requests Further Information From the CHMP

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, was informed on Friday January 27, 2012 after business ...


04 Jan, 2012, 06:00 GMT Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy

 Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the U.S. Food and Drug...


30 Dec, 2011, 06:00 GMT Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Company has raised € 2.5...


15 Dec, 2011, 06:00 GMT Amsterdam Molecular Therapeutics Announces Negative Equity Position

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Company has a negative equity ...


17 Nov, 2011, 06:00 GMT Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today provided its non-audited business update in...


16 Nov, 2011, 06:00 GMT Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency...


25 Oct, 2011, 08:09 BST Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today provided an update on operations and disclosed...


21 Oct, 2011, 12:53 BST Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that the European Medicines Agency's...